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Abstract
Objectives: Ameloblastoma is a benign, locally aggressive odontogenic tumor with
high recurrence rates. Matrix metalloproteinases (MMPs) mediate extracellular integ-
rity in normal and pathological conditions, and exert multiple functions coordinating
inflammation and tumor progression. E-cadherin and beta-catenin are adherence
junction molecules in cell-to-cell connections. We investigated the involvement of
MMP-7, -8, -9, E-cadherin, and beta-catenin in ameloblastoma and the surrounding
extracellular matrix.
Material and methods: Our material consisted of 30–34 tissue samples from
ameloblastoma patients of Helsinki University Hospital. We used immunohistochem-
istry to detect the expression of the biomarkers. Two oral pathologists independently
scored the immunoexpression intensities and statistical calculations were made
based on the results.
Results: E-cadherin expression was weaker in the maxillary than in mandibular
ameloblastomas. Beta-catenin was expressed in the ameloblastoma cell membranes.
We detected MMP-8 and -9 expression in polymorphonuclear neutrophils in the
extracellular area and these MMPs correlated positively with each other. Osteoclasts
lining bone margins and multinuclear giant cells expressed MMP-9. Neither MMP-8
nor MMP-9 immunoexpression could be detected in ameloblastoma cells. MMP-7
expression was seen in some apoptotic cells.
Conclusion: The fact that E-cadherin immunoexpression was weaker in maxillary
compared to mandibular ameloblastomas might associate to earlier recurrences. It
promotes the idea of mandibular and maxillary ameloblastoma exerting differences in
their biologies. We detected MMP-8 and -9 in polymorphonuclear neutrophils which
relates to these MMPs participating in extracellular remodeling through a mild inflam-
matory process. Bone degradation around ameloblastoma may be due to MMP-9 in
osteoclasts but this phenomenon might be an independent process and needs further
investigations.
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1 | INTRODUCTION
Ameloblastomas are the most common odontogenic tumors with an
estimated annual incidence of 0.5/million inhabitants. They are benign
but locally aggressive odontogenic epithelial tumors located to the
dentoalveolar region presenting as an intraosseous or peripheral
lesion. Patients are typically 30–40 years old, though tumors occur in
all age groups (El-Naggar, Chan, Grandis, Takata, & Slootweg, 2017).
Recurrences develop in 20–93% of cases supposedly depending on
the treatment modality (Neagu, et al., 2019). Pathogenesis is currently
based on BRAF and SMO mutations in the mitogen-activated protein
kinase (MAPK) and the Sonic Hedgehog signaling (SSH) pathways,
respectively (Sweeney, et al., 2014). A growing interest focuses on the
extracellular functions and inflammatory activities of the tumor envi-
ronment. Still, the exact tumorigenesis remains to be resolved.
Matrix metalloproteinases (MMP) are a heterogeneous group of
zinc-dependent, genetically distinct but structurally related proteinases
responsible for the degradation and synthesis control of the extracellular
matrix (ECM) and the basement membrane (BM). MMP's also participate
by processing nonmatrix bioactive substrates involved in the membrane
shedding, chemokine, or growth factor modification, and in regulating
the activity of other proteases. They play an important role as the effec-
tive regulators of cell proliferation and differentiation, tissue homeosta-
sis, and immune response (Löffek, Schilling, & Franzke, 2011).
The gelatinase MMP-9, when activated can break down type IV
collagen and gelatin, the main elements of the ECM and BM (Roomi,
Monterrey, Kalinovsky, Rath, & Niedzwiecki, 2009). MMP-9 plays a
crucial role in tumor progression, from angiogenesis, to stromal and
bone remodeling, and ultimately to metastasis (Farina & Mackay,
2014). Various studies confirm and evidence the presence of MMP-9
in ameloblastoma cells and the ECM and BM processings (Anne,
Krisnuhoni, Chotimah, & Latief, 2014; Kumamoto, Yamauchi,
Yoshida, & Ooya, 2003; Ribeiro et al., 2009; Yang, et al., 2018).
MMP-8 or collagenase-2 is a neutrophil derived collagenase
with a multifunctional role in mediating inflammation, and inhibiting
cancer invasion and metastasis. Its protective nature seems to
depend on the tissue of origin (Juurikka, Butler, Salo, Nyberg, &
Åström, 2019). It degrades efficiently type 1 collagen among other
ECM and non-ECM substrates. MMP-8 is thought to play a role in
inflammation and different tumor processes (Juurikka et al., 2019). To
our knowledge, there is no previous studies of the MMP-8 expres-
sion in ameloblastomas.
MMP-7, known as matrilysin, is found constitutively in many epi-
thelial cell types, especially ductal cells of exocrine glands like salivary
glands, liver, breast and colon (Saarialho-Kere, Crouch, & Parks, 1995).
It has a function in tumor invasion, metastasis and as a pro-MMP-2,
-8 and -9 activator. It has also been associated to angiogenesis in
normal physiological processes as well as in cancer progression
(Nishizuka et al., 2001)
Adherens junctions anchor epithelial cells together and mediate
cell and tissue behavior via transmembrane cadherin/catenin-based
complexes bound to intracellular microfilaments. These structures
contribute to the formation of solid tissue and coordinate intra- and
intercellular signaling (Niessen, 2007). E-cadherin is a Ca-dependent
transmembrane protein which is linked intracellularly to p120-, α-, β-,
and γ-catenins (Tian, Liu, Niu, et al., 2011). E-cadherin/beta-catenin
complexes modulate Wnt signaling and are involved in epithelial to
mesenchymal (EMT) and mesenchymal to epithelial (MET) transitions,
which are essential in embryo development, tissue fibrosis, and cancer
progression. Mediators of inflammation, including MMPs, growth
factors, and cytokines may cause dysregulation and loosening of this
adherence complex (Shang, Hua, & Hu, 2017). Via transactivation
of target genes involved, the nuclear accumulation of beta-catenin
promotes tumor progression and proliferation (Brabletz, Jung, Dag,
Hlubek, & Kirchner, 1999) (Figure 1). Beta-catenin can regulate the
expression of the MMP-7 in human colorectal cancer (Brabletz
et al., 1999).
In this study, we explored the expression of MMP-7, -8, -9, beta-
catenin, E-cadherin in the ECM and ameloblastoma tumor cells and
evaluated the role of those markers combined with clinical factors in
predicting recurrence of ameloblastoma.
2 | MATERIAL AND METHODS
2.1 | Patient material
Our series consisted of 34 ameloblastoma patients treated at the
Helsinki University Hospital, Department of Oral and Maxillofacial
Diseases (HUCH). The Department of Pathology (HUSLAB) archives
provided us with the formalin-fixed paraffin-embedded tissue sam-
ples. We have described the patient material in more detail in our pre-
vious study (Kelppe, et al., 2019). Since some samples were no longer
available, 8 cases with recurrent ameloblastoma of which we had no
primary tumor tissue available for our preliminary studies were added
to the series. The Ethics Committee of Surgery and HUCH's Internal
Review Board (Dnro 151/13/03/02/2015) granted their approval for
this study.
2.2 | Immunohistochemistry
For immunohistochemistry, we used 3 μm thick formalin-fixed
paraffin-embedded tissue sections, which we attached on the glass in
60C for 1–2 hr. The samples underwent deparaffinization in xylene.
A graded alcohol series to water rehydrated the tissue. A heated
buffer (Dako ENvision Flex) specific for each antibody functioned as a
heat induced epitope retrieval. For staining, we used Autostainer
480 (Labvision UK Ltd., Suffolk, UK) with Dako REAL EnVision Detec-
tion System, Peroxidase, Rabbit/Mouse (Dako, Glostrup, Denmark).
The primary incubation of each antibody was for 1 hr in +4C and
a secondary HRP-coupled antibody for half an hour. To visualize
results we used either a DAB (brown) or magenta (pink) chromogen. A
hematoxylin incubation for 2 minutes counterstained the nuclei. A
graded alcohol series dehydrated the tissue. The samples were finally
mounted. Primary antibodies were: anti-MMP-7 (1:1000, EMD Mil-
lipore Corporation, Temecula, CA), anti-MMP-8 (1:400), anti- MMP-9
(1:1000, NeoMarkers, Fremont CA and Calbiochem Inc., San Diego,
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CA), antibeta-catenin (1:400, Thermo Fisher Scientific MA), and ant-E-
cadherin (1:100 Thermo Fisher Scientific MA). Colon and oral squa-
mous cell cancer tissues functioned as positive controls. For the
negative control, we did not add the primary antibody.
2.3 | Scoring of immunohistochemistry
Two oral pathologists (J.K. and J.H.) scored independently the staining
expressions without the knowledge of clinical data. All samples were
preliminarily screened to get an overview of intensity differences in
expression. We used a semiquantitative scoring system with the fol-
lowing guidelines: 0 when no expression was present, 1 when we
saw weak reaction or only focal intense reaction, 2 when moderate
diffuse reaction was seen, and 3 when intense diffuse reaction was
seen. In case of disagreement, we agreed upon a consensus. MMP-8
and MMP-9 were scored as 0 = negative, 1 = mild positivity, 2 = strong
positivity. We scored MMP7 expression negative or positive since
positive cells were scarce. All tumors had a similar beta-catenin
staining pattern and were scored either 1 = mild positivity, 2 = moder-
ately positive, or 3 = strongly positive. We scored E-cadherin likewise
as either mild or strong. Positivity less than 10% was considered as
weak expression. Figure 2 shows examples of expression intensities.
2.4 | Statistical analyzes
We sought correlations between MMP-7, -8, -9, beta-catenin, E-
cadherin, age, gender, location, and recurrence. We calculated odds
ratios for MMP-8 and -9, MMP-8/ -9/beta-catenin/and gender, recur-
rence, and location, MMP-8/beta-catenin and age. Scoring results 0 or
1 were relabeled as mild (0) and 2 or 3, were relabeled as strong (1). We
used logistic regression, chi-square tests, and when relevant, 2 by 2 table
functions. We conducted the analyses using R 3.4.2 and RStudio
1.1.383 and considered a p-value equal or less than .05 significant.
3 | RESULTS
The cohort consisted of 34 patients of which 19 were men and
15 women. The age distribution among men was 13–87 and among
women 18–71. Of 34 cases, 24 were mandibular and 10 were maxillary
tumors or from the sinonasal area. The tumor size varied from 7 to
110 mm. Table 1 demonstrates staining results between genders.
Figure 3 shows the expression of MMPs, beta-catenin and E-cadherin
according to size and gender. In male patients, larger tumors seemed to
have decreased expression of E-cadherin and enhanced MMP-9 expres-
sion. In female patients E-cadherin and beta-catenin expression was
stronger in smaller than in larger tumors (Figure 3) but without statistical
significance.
3.1 | MMP-7
MMP-7 was expressed only in apoptotic or mitotic cells in the basal layer
of ameloblastoma tumor tissue which otherwise was negative. There
was also a mild membranous staining. ECM was negative (Figure 2).
3.2 | MMP-8
Polymorphonuclear neutrophils and plasma cells showed MMP-8
immunopositivity but ameloblastoma cells were negative (Figure 2).
MMP-8 positivity correlated with location (mandible/maxilla; p = .026
chi x2-test, but when adjusted for gender and age the correlation was
lost (p = .112).
F IGURE 1 The canonical Wnt/beta-catenin
signaling pathway. Accumulation of beta-catenin
into the cytoplasm or nucleus of the cell helps
maintain the stemness of cells, prompts
tumorigenic qualities, and enhances cancer cell
proliferation and survival. Beta-catenin activity is
controlled by numerous binding partners that
affect stability, cellular localization, and
transcriptional activity. Modified from Shang
et al. (2017). APC, adenomatous polyposis coli;
Axin, scaffold protein; GSK3, glycogen synthase
kinase 3; LPR5/6, lipopolysaccharide like receptor
protein 5/6; P, phosphorylation; TCF/LEF, T-cell
factor/lymphoid enhancing factor
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3.3 | MMP-9
MMP-9 positivity was detected in inflammatory cells, multinuclear
giant cells among inflammatory infiltration, and osteoclasts lining the
bone. Ameloblastoma cells were negative (Figure 2). In logistic regres-
sion, stronger MMP-9 positivity correlated with stronger MMP-8
(p = .015), but the confidence interval (CI) was wide indicating a small
number of cases (OR: 8, 95% CI: 1.5, 42.4).
3.4 | Beta-catenin
Cell membrane expression of beta-catenin was seen in all ameloblastoma
samples, without nuclear expression. Beta-catenin expression in amelo-
blastomas correlated with gender (p = .015), male patients having stronger
expression, but the CIwas once againwide (OR: 6; 95%CI: 1.3, 26.7).
3.5 | E-cadherin
Of 34 cases, we were able to score 30 samples for this study.
Ameloblastomas expressed E-cadherin in most of mandibular
ameloblastomas (66.7%; 20/30) especially in stellate reticulum-like
areas and in peripheral columnal cells where the expression was weak
or negative. Of maxillary tumors 60% (6/10) remained E-cadherin
TABLE 1 Staining results of MMP-8, -9, Beta-catenin, and E-cadherin compared between female and male
MMP-8 (n = 34) MMP-9 (n = 34) Beta-catenin (n = 34) E-cadherin (n = 30)
Gender Female Male Female Male Female Male Female Male
Non orweak expression 12 (35%) 1 (32%) 10 (29%) 11 (32%) 11(32%) 6 (18%) 4 (13%) 6 (20%)
Strong expression 3 (9%) 8 (24%) 5 (15%) 8 (24%) 4 (12%) 13 (38%) 8 (27%) 12 (40%)
F IGURE 2 Demonstrates immunoexpression of MMP-8, -7, -9, beta-catenin, and E-cadherin. Tumor cells did not express MMP-8 (a, b).
Neutrophils expressed MMP-8-positivity presented here as magenta red (a, b). Single apoptotic tumor cells expressed MMP-7 (arrows) (c).
Osteoclasts and fibroblasts in the invasive front expressed MMP-9, while tumor cells remained negative (d-f). All ameloblastomas expressed beta-
catenin (g). Ameloblastoma considered negative for E-cadherin (h) and positive for E-cadherin (j)
F IGURE 3 Demonstrates the difference in tumor size (median in
mm) compared to E-cadherin, Beta-catenin, MMP-8, and -9
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negative or showed only weak expression (Figure 2 and Table 2).
E-cadherin expression in tumors appeared to be patchy with both
positive and negative areas. Regression logistics revealed a correlation
between mandibular location and strong E-cadherin expression
(p = .036; OR: 0.167; 95% CI: 0.031, 0.889). With logistic regression
E-cadherin correlated positively with the beta-catenin expression
(p = .045 with a OR: 5.4; 95% CI: 1.04, 28.5). Unfortunately, the CI
was wide. Although we did not find statistical differences, the often-
recurring maxillary tumors had weak E-cadherin expression in 4 of
6 recurring cases, whereas in recurring mandibular tumors the propor-
tion was 1 out of 5.
4 | DISCUSSION
In this study, we used immunohistochemistry to investigate the
MMP-7, -8, -9, beta-catenin, and E-cadherin immunoexpression in pri-
mary and recurrent ameloblastoma tissue samples from 34 patients. In
contrast to most previous studies (Anne et al., 2014; Pinheiro, Freitas,
Moretti, Jorge, & Jaeger, 2004; Ribeiro et al., 2009; Souza Freitas
et al., 2009; Yang et al., 2018), none of our ameloblastomas expressed
MMP-7 or -9. To our knowledge, there are no previous reports on
MMP-8 immunoexpression in ameloblastomas. In our study, only
inflammatory cells showed MMP-8 positivity, varying from mild to
strong. Beta-catenin was expressed on cell membranes but not, in the
cytoplasm or the nucleus. Though beta-catenin showed positivity in
all ameloblastomas, E-cadherin was unexpectedly negative in 60% of
maxillary tumors. None of our parameters correlated with recurrence.
MMPs are tissue destructing proteolytic enzymes taking part in
the normal and pathological growth and tissue remodeling (Uitto,
Overall, & McCulloch, 2003). Different MMPs have been vastly stud-
ied in both benign, including ameloblastomas, and malignant tumors
proving them to participate in tumor proliferation and progression.
Kumamoto et al. (2003) found stronger MMP-9 positivity in ECM
cells than in the epithelium of ameloblastomas, which is in line with
our results. Since our preliminary staining with a Neomarks antibody
presented negativity in tumor cells, we repeated the test with a
Calbiochem antibody with the same negative outcome.
Ameloblastoma remodels jawbone and thins the cortical plates.
Osteoclasts are known to express MMP-9, and these cells take part in
bone remodeling (Andersen, del Carmen Ovejero, Kirkegaard, Lenhard, &
Foged, 2004). We found MMP-9 positivity in multinucleated giant cells
and osteoclasts as well. Otherwise, MMP-9 was seen in inflammatory
cells, that is, mainly in neutrophilic granulocytes. This could be explained
by the ability of these MMPs to activate and promote inflammatory pro-
cesses in the tumor microenvironment. By activating cytokines, they
might take part in the tumor process as well. As mentioned in previous
studies, the lack of strong immunoexpression of these ECM-destructive
enzymes in tumor tissues indicates the benign nature of ameloblastomas
(Kumamoto et al., 2003; Ribeiro et al., 2009). In male patients, a more
intense MMP-9 positivity in PMN cells correlated with a stronger
MMP-8 expression. This might reflect the fact that male tumors were
often larger in size, as MMP-9 is needed for tissue destruction
while the tumor is still growing, and that MMP-8, and -9 may have
mutual inducers in wound healing and related inflammation. Because
ameloblastoma tumor tissue did not express MMP-9 with neither of the
two different MM-9 –antibodies used, our results challenge the previ-
ous studies where MMP-9 claimed to be expressed by the tumor cells
as well (Pinheiro et al., 2004; Ribeiro et al., 2009; Yang et al., 2018).
Contradictory to our results, Ribeiro et al. (2009) have demonstrated a
tumorous and stromal MMP-9 expression in ameloblastomas. These
seemingly different results might be explained for example by the use of
different antibody clones.
Thiolloy et al. (2009) showed that in mammary tumors osteoclast
derived MMP-7 participated in tumor induced osteolysis and tumor
growth, and that MMP-7 null mice had fewer osteoclasts at the
tumor-bone interface than did the wild-type controls. In contrary, we
could not detect MMP-7 immunoexpression in osteoclasts. This raises
the question, could the absence of osteoclast derived MMP-7 in
ameloblastomas provide protection against more aggressive behavior?
In colorectal cancer, nuclear beta-catenin can regulate MMP-7 expres-
sion (Brabletz et al., 1999). In our material neither nuclear beta-
catenin nor MMP-7 expression were detected in ameloblastoma cells
except for some single positive apoptotic or mitotic cells.
In normal epithelial tissue, E-cadherin/beta-catenin structures pro-
vides a steady and adherent cell-to-cell junction and normal cell polar-
ity. The loss of E-cadherin is a principal event in metastatic progression
and invasive behavior in gastric cancer (Wu, Zhuang, Jiang, et al.,
2016). The downregulation of this protein might be involved in the
EMT where polarized epithelial cells transform into a mesenchymal
TABLE 2 Comparison between
location (mandibular or maxillary tumor),
E-cadherin staining intensity, and
recurrence
Weak E-cadherin Strong E-cadherin Total
Mandible
No recurrence 3 (10%) 12 (40%) 15 (50%)
Recurrence 1 (3%) 4 (13.3%) 5 (16.7%)
Maxilla
No recurrence 2 (6.7%) 2 (6.7%) 4 (13.3%)
Recurrence 4 (13.3%) 2 (6.7%) 6 (20%)
Total 10 (33.3%) 20 (66.7%) 30 (100%)
Note: For location and E-cadherin expression: p = .045, risk ratio 2.0, 95% CI: 0.91–4.41. No significant
correlations between recurrence and E-cadherin was detected.
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phenotype thus facilitating migration (Pasquier, Abu-Kaoud, Al Thani, &
Rafii, 2015; Shamir, et al., 2014). In addition, the accumulation of
nuclear beta-catenin activates the target genes C-Myc, CyclinD1,
MMP-7, Twist, Snail, and Slug—all connected to EMT. In our material
we could not detect MMP-7 activation by beta-catenin.
It has been shown that when ameloblastomas lose E-cadherin
expression they gain Snail, Slug, and Twist expression and this
shift might allow tumors to gain EMT proprieties (Kurioka, Wato,
Iseki, Tanaka, & Morita, 2017). We could not see morphological
cell changes from epithelial to mesenchymal in our maxillary
ameloblastomas, but these repressors gaining function could possibly
explain the loss of E-cadherin in these easily recurring tumors.
Desmoplastic ameloblastomas differ in morphology from conventional
ameloblastomas. These ameloblastoma cells are more spindle-like
and are surprisingly shown to demonstrate smooth muscle actin
(SMA) positivity (Siar & Ng, 2019). In our study, most desmoplastic
ameloblastoma cell strands expressed both E-cadherin and membrane
beta-catenin showing epithelial nature. Still, the literature suggests
desmoplastic ameloblastomas to potentially have aggressive biologic
behavior (Sun, Wu, Cheng, Zwahlen, & Zhao, 2009). The expression
of stem cell markers has been demonstrated in ameloblastomas
reminding that these tumors probably possess multipotent properties
enabling constant proliferation and expression of several types of mol-
ecules including p63, CD10, and the previously mentioned SMA.
We found that 60% of the maxillary tumors and 20% of the
mandibular tumors had only mild E-cadherin immunoexpression. This
might reflect the fact that maxillary tumors recur more often than man-
dibular ones. These findings could be further investigated by staining for
Vimentin, Snail, Twist, and N-cadherin to exclude the possibility minor
EMT-like changes in maxillary tumors. Further research is also needed
to solve the mechanism behind the weaker expression of E-cadherin in
maxillary ameloblastomas and its possible role in tumor recurrence.
In our material, ameloblastoma tissue showed solely cell membra-
nous expression of beta-catenin without cytoplasmic or nuclear
expression. This might reflect a protective role inhibiting invasion, as
nuclear beta-catenin expression is connected to the metastatic poten-
tial (Brabletz et al., 1999). The role of beta-catenin immunoexpression
in metastatic ameloblastomas and ameloblastic carcinomas could be
worth investigating.
This study would have benefited from a larger case cohort espe-
cially of maxillary tumors. Another limiting factor in this study is the
semiquantitative scoring method which provides approximate esti-
mates of the exact clinical situation. With a larger cohort and compute
scoring program more precise results could be obtained.
In conclusion, to our estimate, inflammatory cells expressing MMP-8
and -9 might promote tumor growth by providing extracellular degrada-
tion or cytokine activation. In maxillary tumors, the weaker expression of
E-cadherin might also facilitate tumor growth and promote recurrence.
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